Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis
Katherine B Hisert1, Timothy P Birkland1, Kelly Q Schoenfelt2
1Dept of Medicine, University of Washington, Seattle, WA, USA.
Abstract:
This study demonstrates that initiation of the CFTR modulator ivacaftor in people with cystic fibrosis and susceptible http://bit.ly/2TeI6LG.
Insights
This study shows that starting ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, benefits individuals with cystic fibrosis. Early treatment with ivacaftor improves health outcomes for eligible patients.
Area of Science:
- Medical Research
- Pharmacology
Background:
- Cystic fibrosis (CF) is a genetic disorder affecting multiple organs.
- The cystic fibrosis transmembrane conductance regulator (CFTR) protein is crucial for ion transport.
- Defective CFTR function leads to CF symptoms.
Purpose of the Study:
- To evaluate the impact of initiating ivacaftor treatment in individuals with cystic fibrosis.
- To assess the clinical benefits and outcomes associated with ivacaftor therapy.
Main Methods:
- Observational study design.
- Analysis of patient data following ivacaftor initiation.
- Assessment of relevant clinical endpoints.
Main Results:
- Initiation of ivacaftor demonstrated positive effects in people with cystic fibrosis.
- Specific susceptible populations showed notable improvements.
- Further details on efficacy and safety are presented.
Conclusions:
- Ivacaftor is an effective modulator for treating cystic fibrosis in susceptible individuals.
- Early initiation of CFTR modulator therapy can be beneficial.
- This highlights the importance of personalized medicine in CF treatment.
More Related Videos
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
